Psychiatrist.com

Bipolar disorder (BD) is a recurrent, episodic illness. Long-term pharmacotherapy is central to relapse prevention, yet treatment nonadherence is common and clinically consequential, as it is consistently linked to higher risks of relapse, hospitalization, and suicidality, as well as greater overall illness burden.1–4 Moreover, nonadherence in BD is often dri...

To the Editor: On April 18, 2026, President Donald Trump signed an executive order directing the US Food and Drug Administration (FDA) to fast-track review of psychedelic drugs, including psilocybin and ibogaine, and allocating $50 million in federal funding toward their clinical development.1 This unprecedented policy action places psychedelics firmly within...

Have you ever evaluated a patient with chronic abdominal pain, early satiety, nausea, vomiting, or weight loss and wondered whether an unrecognized psychiatric disorder might be contributing to the presentation? Have you seen patchy alopecia, broken hairs of uneven length, or repetitive grooming behaviors and been uncertain whether to ask about chewing or swa...

Butorphanol is a synthetic opioid with partial agonist-antagonist receptor activity in the μ and ĸ receptors.1 It is approved by the US Food and Drug Administration as an analgesic. Because of the antagonist activity, the addiction potential is considered less than that of other opioids. Animal studies have found that butorphanol has rewarding properties and ...